Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00102778
Status:
TERMINATED
Last Update Posted:
2017-05-30
First Post:
2005-02-01
Brief Title:
GW873140 In Combination With Kaletra In HIV Infected Subjects
Sponsor:
ViiV Healthcare
Organization:
ViiV Healthcare
Study Overview
Official Title:
A Phase IIb 96 Week Randomized Open-label Multicenter Parallel Group Repeat Dose Study to Evaluate the Safety Tolerability PK and Antiviral Effect of Different Doses and Regimens of GW873140 in Combination With Kaletra Lopinavir and Ritonavir in HIV-1 Infected Antiretroviral Therapy naïve Subjects
Status:
TERMINATED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Kaletra in HIV infected untreated subjects
Detailed Description:
A Phase IIb 96 week randomized open-label multicenter parallel group repeat dose study to evaluate the safety tolerability pharmacokinetics and antiviral effect of different doses and regimens of GW873140 in combination with Kaletra lopinavir and ritonavir in HIV-1 infected antiretroviral therapy naive subjects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None